Personalis
Personalis aims to transform the active management of cancer through breakthrough personalized testing. Its advanced genomic tests detect ultra-low traces of minimal residual disease and recurrence, uncover deeper insights for therapy selection and power the design of individualized neoantigen therapies.
Latest Personalis Content
Product News
Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023
Personalis, Inc. has announced it will present new clinical data as scientific posters at the American Society of Clinical Oncology Annual Meeting 2023, which convenes from June 2-6, 2023, in Chicago, Ill.
Product News
Personalis, National Cancer Center Hospital East and Ono Collaborate To Better Predict Immunotherapy Response for Rectal Cancer
Personalis, Inc., National Cancer Center and Ono Pharmaceutical Co., Ltd. have announced they have entered into a collaborative agreement to examine the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for resectable rectal cancer with mismatch repair deficiency.
Product News
Personalis, ABRCC and Criterium Announce Major Prospective Clinical Trial
Personalis, Inc. has announced it has partnered with the Academic Breast Cancer Consortium and Criterium to carry out a prospective clinical trial to evaluate the clinical performance of the NeXT Personal® test.
Article
Redefining Cancer-Free With ctDNA
In this article, we dive into MRD and how it promises to both address an unmet need in the care of cancer patients and ultimately help patients live longer lives with less uncertainty.
Product News
Personalis Joins Top UK Cancer Research Organizations To Evaluate Earlier Cancer Recurrence Detection
Personalis, Inc., Cancer Research UK’s Cancer Research Horizons, University College London and the Francis Crick Institute have announced a collaboration to deploy a personalized liquid biopsy-based research assay, for the TRACERx study.
Product News
Personalis Selected for Clinical Research After Successful Evaluation of Residual Disease Assay
Personalis, Inc. has announced it will continue its collaboration with AstraZeneca to explore ultra-sensitive molecular residual disease measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development.
Product News
Personalis and Moderna Sign New Agreement To Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
The platform will be used to sequence genomic information from a patient’s tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.
Product News
Personalis and UCSF To Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer
Personalis has announced a collaboration with UC San Francisco that will deploy a personalized liquid biopsy-based research use only assay for a study of patients with colorectal cancer.
Industry Insight
Using Machine Learning To Enhance Biomarkers for Cancer Immunotherapy
In this interview, we spoke to Rachel Marty Pyke PhD, manager of bioinformatics science at Personalis, to find out how machine learning can be used to detect genomic instability as a biomarker for cancer immunotherapy.
Product News
Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform
Personalis has announced the issuance of a key US Patent related to its industry-leading minimal residual disease (MRD) and recurrence platform, NeXT Personal.
Advertisement
